BridgeMD
New treatment option for Coronary Artery Disease
Official title Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients
ClinicalTrials.gov ID: NCT05936606
What this study is testing
What is Clopidogrel monotherapy?
Clopidogrel monotherapy is an investigational medicine, given as an once-daily, being studied as a potential treatment for coronary artery disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement. However, concerns remain about the safety of long-term clopidogrel monotherapy in high-risk patients with HPR (high platelet reactivity) who do not respond adequately to clopidogrel.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 80
You may be able to join if
- Patients \> 18 years old
- Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (± 3 months) ago.
- At least one high risk characteristics of ischemic events High risk patients
- Acute coronary syndrome
- Previous history of cerebrovascular accidents
You likely can't join if
- Patients \> 80 years old
- Pregnant women or women with potential childbearing
- Life expectancy \< 1 year
- Refusal or inability to understand of informed consent
- Patients eligible to long-term anticoagulation therapy
- Patients with major bleeding events in previous 3 months before randomization
See the full eligibility criteria
- Patients \> 18 years old
- Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (± 3 months) ago.
- At least one high risk characteristics of ischemic events High risk patients
- Acute coronary syndrome
- Previous history of cerebrovascular accidents
- Previous history of peripheral artery intervention
- Heart failure
- Diabetes mellitus requiring medication
- Chronic kidney disease (regardless of requirement of renal replacement therapy) High risk lesions
- Left main disease
- Multivessel disease, 2- or 3- vessels
- Bifurcation lesions requiring 2 or more stents
- Chronic total occlusion
- In-stent restenosis
- Graft lesions
- Diffuse long lesion requiring stent(s) with total stent length ≥28 mm
- Lesion at small sized vessel requiring stent(s) with stent diameter ≤2.5 mm
- Calcified lesions requiring atherectomy
- Patients \> 80 years old
- Pregnant women or women with potential childbearing
- Life expectancy \< 1 year
- Refusal or inability to understand of informed consent
- Patients eligible to long-term anticoagulation therapy
- Patients with major bleeding events in previous 3 months before randomization
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.